Literature DB >> 32442108

Predictors of mortality in fibrosing pulmonary sarcoidosis.

Florence Jeny1, Yurdagül Uzunhan2, Maxime Lacroix3, Thomas Gille4, Pierre-Yves Brillet5, Annelyse Nardi6, Diane Bouvry2, Carole Planès4, Hilario Nunes2, Dominique Valeyre2.   

Abstract

INTRODUCTION: Pulmonary fibrosing sarcoidosis is associated with increased mortality. This study was aimed to explore the prognosis value of a panel of parameters for predicting mortality.
METHODS: This retrospective study included 216 patients with confirmed stage 4 pulmonary sarcoidosis. Stage 4 diagnosis date served as baseline. The following information was systematically present at baseline: epidemiological characteristics; treatments; pulmonary function; composite physiologic index (CPI); systolic pulmonary artery pressure at echocardiography; pulmonary fibrosis extent, main pulmonary artery/ascending aorta diameters ratio (MPAD/AAD) and MPAD/body surface area (BSA) measured and calculated using computed tomography, Walsh's algorithm based on CPI, lung fibrosis extent and MPAD/AAD ratio, and modified Walsh's algorithm with MPAD/BSA replacing MPAD/AAD allowed to estimate good or bad prognosis profiles. The primary outcome of the study was all cause mortality and lung transplantation. The value of baseline parameters was tested as predictors of mortality using univariate and multivariate analyses.
RESULTS: Median follow-up was 105 months. There were 41 deaths and 5 transplantations. At multivariate analysis, survival was independently predicted by several parameters including CPI, lung fibrosis extent, pulmonary hypertension at echography or MPAD/BSA ratio, Walsh's algorithm, and geographic origin. The modified Walsh's algorithm was most highly predictive.
CONCLUSION: Survival was best predicted by geographic origin, lung fibrosis extent, PH at echography or MPAD/BSA ratio, as well as by various scores among them the modified Walsh's algorithm had very high predictive value thanks to MPAD/BSA ratio which accurately predicted mortality.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mortality; Prognosis; Pulmonary fibrosis; Pulmonary hypertension; Sarcoidosis

Mesh:

Year:  2020        PMID: 32442108     DOI: 10.1016/j.rmed.2020.105997

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  4 in total

1.  Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study.

Authors:  Robert P Baughman; Rohit Gupta; Marc A Judson; Elyse E Lower; Surinder S Birring; Jeffrey Stewart; Rebecca Reeves; Athol U Wells
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

2.  Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis.

Authors:  M C Schimmelpennink; D B Meek; A D M Vorselaars; L C M Langezaal; C H M van Moorsel; J J van der Vis; M Veltkamp; J C Grutters
Journal:  Respir Res       Date:  2022-06-25

3.  Hypoxia Promotes a Mixed Inflammatory-Fibrotic Macrophages Phenotype in Active Sarcoidosis.

Authors:  Florence Jeny; Jean-François Bernaudin; Dominique Valeyre; Marianne Kambouchner; Marina Pretolani; Hilario Nunes; Carole Planès; Valérie Besnard
Journal:  Front Immunol       Date:  2021-08-11       Impact factor: 7.561

Review 4.  The role of PET in the management of sarcoidosis.

Authors:  Robert J Vender; Hamad Aldahham; Rohit Gupta
Journal:  Curr Opin Pulm Med       Date:  2022-07-16       Impact factor: 2.868

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.